Alnylam Pharmaceuticals, Inc. ALNY
Set alert
At close · Oct 30
After hours · Oct 30, 7:36 PM ET
- YTD
- -58.51%
- 1 year
- -63.30%
- Open
- 172.70
- Prev close
- 174.00
- Mkt cap
- 22.10B
- Vol
- 7.06M
- Avg vol
- 1.79M
- EPS
- 5.93
- P/E
- 27.82
- Div yield
- 0.00%
More statistics
- Low
- 163.30
- High
- 180.61
- Forward P/E
- 13.69
- Beta
- 0.00
- Short ratio
- 5.02
- Inst. own
- 101.53%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 11, 2027
- 50-d avg
- 237.78
- 200-d avg
- 286.49
- 1y target
- 345.30
MAX chart
Events in this range
- Oct 30, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 30, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Oct 30, 2026Rating: Goldman Sachs · Buy → Buy
- Oct 30, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Oct 30, 2026Downgrade: Bernstein · Outperform → Market Perform
- Oct 30, 2026Rating: TD Cowen · Buy → Buy
Signals (82)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| MACD: Sell Signal | Feb 1, 2026 | 9 months ago |
| SMA: Bearish | Jan 1, 2026 | 10 months ago |
| RSI: Overbought | Jul 1, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 1, 2024 | 2 years ago |
| SMA: Bullish | Jun 1, 2024 | 2 years ago |
| SMA: Bullish | Jun 1, 2024 | 2 years ago |
| SMA: Bearish | Jan 1, 2024 | 2 years ago |
| SMA: Bearish | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| SMA: Bearish | Sep 1, 2023 | 3 years ago |
| MACD: Sell Signal | May 1, 2023 | 3 years ago |
| SMA: Bearish | Apr 1, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 1, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Apr 1, 2022 | 4 years ago |
| SMA: Bullish | Feb 1, 2022 | 4 years ago |
| SMA: Bearish | Jan 1, 2022 | 4 years ago |
| SMA: Bearish | Jan 1, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 1, 2022 | 4 years ago |
| SMA: Bullish | Nov 1, 2021 | 5 years ago |
| SMA: Bearish | Oct 1, 2021 | 5 years ago |
| RSI: Overbought | Aug 1, 2021 | 5 years ago |
| MACD: Buy Signal | Jun 1, 2021 | 5 years ago |
| MACD: Sell Signal | May 1, 2021 | 5 years ago |
| SMA: Bullish | Jan 1, 2021 | 5 years ago |
| SMA: Bearish | Oct 1, 2020 | 6 years ago |
| SMA: Bullish | Nov 1, 2019 | 7 years ago |
| MACD: Buy Signal | Nov 1, 2019 | 7 years ago |
| SMA: Bullish | Aug 1, 2019 | 7 years ago |
| SMA: Bearish | May 1, 2019 | 7 years ago |
| SMA: Bearish | May 1, 2019 | 7 years ago |
| SMA: Bullish | Mar 1, 2019 | 7 years ago |
| SMA: Bullish | Mar 1, 2019 | 7 years ago |
| SMA: Bearish | Oct 1, 2018 | 8 years ago |
| SMA: Bearish | Sep 1, 2018 | 8 years ago |
| SMA: Bullish | Aug 1, 2018 | 8 years ago |
| MACD: Sell Signal | Jul 1, 2018 | 8 years ago |
| SMA: Bearish | Apr 1, 2018 | 8 years ago |
| RSI: Overbought | Nov 1, 2017 | 9 years ago |
| SMA: Bullish | Jun 1, 2017 | 9 years ago |
| MACD: Buy Signal | Jun 1, 2017 | 9 years ago |
| SMA: Bullish | Apr 1, 2017 | 9 years ago |
| SMA: Bearish | Jan 1, 2016 | 10 years ago |
| MACD: Sell Signal | Sep 1, 2015 | 11 years ago |
| SMA: Bearish | Aug 1, 2015 | 11 years ago |
| RSI: Overbought | Jul 1, 2015 | 11 years ago |
| RSI: Overbought | May 1, 2015 | 11 years ago |
| RSI: Overbought | Mar 1, 2015 | 11 years ago |
| RSI: Overbought | Nov 1, 2014 | 12 years ago |
| MACD: Buy Signal | Sep 1, 2014 | 12 years ago |
| SMA: Bullish | Aug 1, 2014 | 12 years ago |
| MACD: Sell Signal | Jul 1, 2014 | 12 years ago |
| SMA: Bearish | Apr 1, 2014 | 12 years ago |
| RSI: Overbought | May 1, 2013 | 13 years ago |
| SMA: Bullish | Jun 1, 2012 | 14 years ago |
| SMA: Bearish | Mar 1, 2012 | 14 years ago |
| SMA: Bullish | Feb 1, 2012 | 14 years ago |
| SMA: Bullish | Jan 1, 2012 | 14 years ago |
| MACD: Buy Signal | Dec 1, 2011 | 14 years ago |
| SMA: Bearish | Oct 1, 2009 | 17 years ago |
| SMA: Bullish | Jun 1, 2009 | 17 years ago |
| SMA: Bearish | Jan 1, 2009 | 17 years ago |
| SMA: Bullish | Dec 1, 2008 | 17 years ago |
| SMA: Bearish | Oct 1, 2008 | 18 years ago |
| SMA: Bearish | Oct 1, 2008 | 18 years ago |
| SMA: Bullish | Jul 1, 2008 | 18 years ago |
| SMA: Bearish | Jun 1, 2008 | 18 years ago |
| SMA: Bullish | May 1, 2008 | 18 years ago |
| SMA: Bearish | Mar 1, 2008 | 18 years ago |
| MACD: Sell Signal | Mar 1, 2008 | 18 years ago |
| MACD: Buy Signal | Sep 1, 2007 | 19 years ago |
| RSI: Overbought | Sep 1, 2007 | 19 years ago |
| SMA: Bullish | Jul 1, 2007 | 19 years ago |
| SMA: Bearish | May 1, 2007 | 19 years ago |
| MACD: Sell Signal | Apr 1, 2007 | 19 years ago |
| SMA: Bullish | Oct 1, 2006 | 20 years ago |
| RSI: Overbought | Oct 1, 2006 | 20 years ago |
| SMA: Bearish | Jul 1, 2006 | 20 years ago |
| RSI: Overbought | Feb 1, 2006 | 20 years ago |
Key statistics
- Market cap
- 22.10B
- Enterprise value
- 22.71B
- Trailing P/E
- 27.82
- Forward P/E
- 13.69
- PEG ratio
- 0.22
- Price / sales
- 4.41
- Price / book
- 6.13
- EPS (TTM)
- 5.93
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 53.68%
- Revenue (TTM)
- 5.01B
- Revenue growth
- 16.70%
- Free cash flow
- 76.92M
- Total cash
- 3.59B
- Total debt
- 3.00B
- Return on equity
- 140.24%
- Shares outstanding
- 133.94M
- Short % of float
- 6.54%
- 50-day average
- 237.78
- 200-day average
- 286.49
Analyst view
Consensus: buy
- Target (low)
- 220.00
- Target (mean)
- 345.30
- Target (high)
- 489.00
- Strong buy6
- Buy16
- Hold8
- Sell0
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 2.44.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 1.75 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 1.66 | 16.26 | +14.60 | +879.52% |
| Jul 30, 2026 | Jun 30, 2026 | 1.63 | 1.21 | -0.42 | -25.77% |
| Apr 30, 2026 | Mar 31, 2026 | 0.872 | 1.51 | +0.64 | +73.17% |
| Feb 12, 2026 | Dec 31, 2025 | 1.16 | 0.82 | -0.34 | -29.31% |
| Oct 30, 2025 | Sep 30, 2025 | 0.561 | 1.84 | +1.28 | +227.99% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | TD Cowen | main | Buy | Buy |
| Oct 30, 2026 | Bernstein | down | Outperform | Market Perform |
| Oct 30, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | Goldman Sachs | main | Buy | Buy |
| Oct 30, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | RBC Capital | main | Outperform | Outperform |
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alnylam.com
News
- TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354
- Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240
- Goldman Sachs Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320
- Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $220
- ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
- RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $280
- This Honeywell Aerospace Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
- Raymond James Downgrades Alnylam Pharmaceuticals to Outperform, Lowers Price Target to $315
- Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop
- Needham Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $243
Your note
Sign in to keep a note on ALNY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BONNEY MICHAEL W | Director | Sale | Aug 17, 2025 | 20,804 |
| FITZGERALD KEVIN JOSEPH | Officer | Sale | Mar 4, 2026 | 21,106 |
| GARG PUSHKAL | Officer | Sale | Mar 4, 2026 | 19,374 |
| GREENSTREET YVONNE L | Chief Executive Officer | Stock Award(Grant) | Sep 17, 2026 | 96,209 |
| POULTON JEFFREY V | Chief Financial Officer | Sale | Mar 3, 2026 | 61,862 |
| PYOTT DAVID E I | Director | Sale | May 31, 2026 | 29,482 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.23% | 15,023,962 | 2.48B | Jun 29, 2026 |
| Capital World Investors | 8.33% | 11,144,846 | 1.84B | Jun 29, 2026 |
| Blackrock Inc. | 8.15% | 10,907,675 | 1.80B | Jun 29, 2026 |
| Capital Research Global Investors | 7.29% | 9,750,699 | 1.61B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.89% | 6,538,390 | 1.08B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.51% | 6,029,478 | 994.86M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund of America | 6.70% | 8,960,487 | 1.48B | Sep 29, 2026 |
| Amcap Fund | 3.38% | 4,526,680 | 746.90M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 4,239,087 | 699.45M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.16% | 2,893,030 | 477.35M | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.09% | 2,794,074 | 461.02M | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.60% | 2,136,580 | 352.54M | Jul 30, 2026 |